Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06549478

A Pilot Study of Biology-Guided Radiation Therapy for Painful Bone Metastases

Led by City of Hope Medical Center ยท Updated on 2025-09-17

24

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

C

City of Hope Medical Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating biology-guided radiation therapy (BgRT) for patients experiencing painful bone metastases from cancer. This phase 1 clinical trial aims to assess the safety and effectiveness of a single-dose BgRT treatment in reducing pain and improving quality of life for these patients. BgRT is an innovative radiation technique that uses live data from positron emission tomography (PET) scans to precisely target active tumors during treatment. Participants receive a single fraction of BgRT at a dose of 14 gray on day 0. PET/computed tomography (CT) scans are performed during the study and optionally during follow-up. The trial monitors patients over time to track pain response, toxicity, disease progression at treated sites, and rates of re-irradiation. During the study, patients undergo pain and quality of life assessments, imaging scans such as PET/CT and MRI, and clinical evaluations at 2 weeks, 3 months, and then every 3 months up to one year. Researchers collect data on adverse events, patient-reported outcomes, and radiographic evidence to evaluate the treatment's impact and safety over a year-long follow-up period.

CONDITIONS

Brief Title

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Documented informed consent from the participant or legally authorized representative
  • Age 18 years or older
  • ECOG performance status of 0 to 2
  • Pathologic diagnosis of cancer
  • Painful bone metastases with a pain score of at least 2 on a 0-10 scale
  • Concurrent treatment allowed for up to 3 radiation fields
  • Target bone lesions with a standardized uptake value maximum (SUVmax) greater than 6 on diagnostic PET
  • Target bone lesion size between 1.5 and 5 cm
  • Pre-screening confirms treatment can be administered within dose constraints
  • Stable brain metastases if present, treated prior to enrollment with stable MRI findings at 3 months
  • Life expectancy of at least 6 months
  • Off systemic cancer therapy for at least one week before and after study treatment
  • Ability to complete pain and quality of life assessments without cognitive impairment
Not Eligible

You will not qualify if you...

  • Prior radiation therapy to the treatment sites
  • Untreated spinal cord compression
  • Pathologic fracture at the treatment site
  • Serious medical conditions preventing radiotherapy
  • Inability to undergo PET/CT scan
  • Pregnancy or breastfeeding
  • Investigator judgment that the patient is unsuitable or unlikely to comply with study procedures
  • Cognitive impairments preventing completion of study assessments or questionnaires

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single day (Day 0)

Participants receive a single dose of biology-guided radiation therapy (BgRT) for painful bone metastases.

1 treatment visit (in-person)

Follow-up

Duration - Up to 1 year

Participants are monitored for safety, pain response, quality of life, and disease progression after treatment.

Visits at 2 weeks, 3 months, and every 3 months thereafter for up to 1 year

Trial Site Locations

Total: 1 location

1

City of Hope Medical Center

Duarte, California, United States, 91010

Actively Recruiting

Loading map...

Research Team

Y

Yi-Jen Chen, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Phase 1/2 Study of LabVax 3(22)-23 and GM-CSF Alone or Wit...

Advanced Adenocarcinoma

Actively Recruiting

1 location

Arginine With Whole Brain Radiation Therapy for the Treatmen...

Metastatic Malignant Neoplasm in the Brain

Actively Recruiting

1 location

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells...

Metastatic Malignant Solid Neoplasm

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here